Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-19-021149
Filing Date
2019-04-12
Accepted
2019-04-12 17:22:52
Documents
5
Effectiveness Date
2019-04-12

Document Format Files

Seq Description Document Type Size
1 DEFA14A a19-7460_3defa14a.htm DEFA14A 32360
2 GRAPHIC g74603bci001.gif GRAPHIC 71090
3 GRAPHIC g74603bci002.gif GRAPHIC 117413
4 GRAPHIC g74603bci003.gif GRAPHIC 33181
5 GRAPHIC g74603bci004.gif GRAPHIC 4774
  Complete submission text file 0001104659-19-021149.txt   345688
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-33137 | Film No.: 19747078
SIC: 2834 Pharmaceutical Preparations